Detection of Myocardial Damage in Patients With Sarcoidosis

• Published in: Circulation (New York, N.Y.) Vol. 120; no. 20; pp. 1969 - 1977
• Main Authors: PATEL, Manesh R, CAWLEY, Peter J, JUDD, Robert M, KIM, Raymond J, HEITNER, John F, KLEM, Igor, PARKER, Michele A, JAROUDI, Wael A, MEINE, Trip J, WHITE, James B, ELLIOTT, Michael D, KIM, Han W
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 17-11-2009
• Subjects: Adult; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Chronic Disease; Coronary heart disease; Death; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Female; Follow-Up Studies; Heart; Heart Diseases - diagnostic imaging; Heart Diseases - etiology; Heart Diseases - mortality; Heart Diseases - physiopathology; Humans; Magnetic Resonance Imaging; Male; Medical sciences; Middle Aged; Radiography; Sarcoidosis - complications; Sarcoidosis - diagnostic imaging; Sarcoidosis - mortality; Sarcoidosis - physiopathology; Stroke Volume; Human; magnetic resonance imaging; Sarcoidosis; Cardiomyopathy; Heart disease; Systemic disease; Cardiovascular disease; Medical screening; Myocardial disease; Nuclear magnetic resonance imaging
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/CIRCULATIONAHA.109.851352

In patients with sarcoidosis, sudden death is a leading cause of mortality, which may represent unrecognized cardiac involvement. Delayed-enhancement cardiovascular magnetic resonance (DE-CMR) can detect minute amounts of myocardial damage. We sought to compare DE-CMR with standard clinical evaluation for the identification of cardiac involvement.
Eighty-one consecutive patients with biopsy-proven extracardiac sarcoidosis were prospectively recruited for a parallel and masked comparison of cardiac involvement between (1) DE-CMR and (2) standard clinical evaluation with the use of consensus criteria (modified Japanese Ministry of Health [JMH] guidelines). Standard evaluation included 12-lead ECG and at least 1 dedicated non-CMR cardiac study (echocardiography, radionuclide scintigraphy, or cardiac catheterization). Patients were followed for 21+/-8 months for major adverse events (death, defibrillator shock, or pacemaker requirement). Patients were predominantly middle-aged (46+/-11 years), female (62%), and black (73%) and had chronic sarcoidosis (median, 7 years) and preserved left ventricular ejection fraction (median, 56%). DE-CMR identified cardiac involvement in 21 patients (26%) and JMH criteria in 10 (12%, 8 overlapping), a >2-fold higher rate for DE-CMR (P=0.005). All patients with myocardial damage on DE-CMR had coronary disease excluded by x-ray angiography. Pathology evaluation in 15 patients (19%) identified 4 with cardiac sarcoidosis; all 4 were positive by DE-CMR, whereas 2 were JMH positive. On follow-up, 8 had adverse events, including 5 cardiac deaths. Patients with myocardial damage on DE-CMR had a 9-fold higher rate of adverse events and an 11.5-fold higher rate of cardiac death than patients without damage.
In patients with sarcoidosis, DE-CMR is more than twice as sensitive for cardiac involvement as current consensus criteria. Myocardial damage detected by DE-CMR appears to be associated with future adverse events including cardiac death, but events were few, and this needs confirmation in a larger cohort.